Form 4: Merit Medical Systems COO Neil Peterson Reports Acquisition of Restricted Stock Units
SEC Form 4 Filing
Neil Peterson, Chief Operating Officer of Merit Medical Systems, reports the acquisition of 7,319 restricted stock units (RSUs) on March 4, 2024.
Summary
- On March 4, 2024, Neil Peterson, the Chief Operating Officer of Merit Medical Systems, acquired 7,319 restricted stock units (RSUs).
- These RSUs vest in four equal annual installments, contingent upon Peterson's continued service.
- Each RSU represents the right to receive one share of Merit Medical Systems common stock upon vesting.
- Peterson also holds non-qualified stock options with various exercise prices and expiration dates.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a standard disclosure of executive compensation. The grant of RSUs is generally viewed positively as it aligns management interests with shareholders.
Positives
- The grant of RSUs aligns the executive's interests with those of the shareholders, incentivizing continued service and performance.
Future Outlook
The RSUs vest over four years, suggesting an expectation of continued service from the COO.
Industry Context
Form 4 filings are routine disclosures required by the SEC to provide transparency regarding insider transactions in publicly traded companies.
Comparison to Industry Standards
- Stock option and RSU grants are common forms of executive compensation in the medical device industry, used to align management incentives with shareholder value.
- Comparable companies such as Boston Scientific, Medtronic, and Stryker also utilize stock options and RSUs in their executive compensation packages.
- The vesting schedules and exercise prices are generally in line with industry practices.
Stakeholder Impact
- Shareholders: Transparency regarding executive compensation.
- Employees: Provides insight into the company's compensation practices.
- Management: Aligns interests with shareholders through equity-based compensation.
Next Steps
- Continued monitoring of insider transactions for further insights into management's perspective on the company's prospects.
Key Dates
| Date | Description |
|---|---|
| 03/02/2019 | First vesting date for non-qualified stock options with an exercise price of $44.8 |
| 04/25/2020 | First vesting date for non-qualified stock options with an exercise price of $54.4 |
| 08/19/2022 | First vesting date for non-qualified stock options with an exercise price of $68.33 |
| 02/28/2024 | First vesting date for non-qualified stock options with an exercise price of $70.58 |
| 03/04/2024 | Date of transaction: Acquisition of 7,319 restricted stock units (RSUs) |
| 03/06/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.